Infections should be treated with appropriate local or systemic antifungal therapy while remaining on Trelegy Ellipta, though Trelegy Ellipta may need to be interrupted in some cases. Patients ...
Nevertheless, GSK R&D chief Hal Barron thinks the triple therapy is still on track for a regulatory filing in uncontrolled asthma once the full dataset is available, and that could extend Trelegy ...
GlaxoSmithKline is set to launch its COPD triple therapy in the US - and must now show that it can maximise sales of the drug with blockbuster potential. Approved yesterday by the FDA, Trelegy ...
Hosted on MSN2mon
Environmentally Friendlier COPD Inhaler May Also Be More EffectiveThere was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic ... umeclidinium-vilanterol (Trelegy Ellipta) over median ...
Trelegy Ellipta, a triple-therapy inhaler containing an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta-agonist (LABA), was found to offer ...
Singapore’s Health Sciences Authority (HSA) has expanded the label of GlaxoSmithKline (GSK)’s Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback